Safety and Tolerability of Combining the IDO-Inhibitor Indoximod with Re-Irradiation for Pediatric Patients with Progressive Brain Tumors Treated on the NLG-2105 Phase 1 Trial (NCT02502708)

PEDIATRIC BLOOD & CANCER(2017)

引用 0|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要